| Literature DB >> 32101308 |
Yves Rolland1,2,3, Neda Tavassoli1,2, Philipe de Souto Barreto1,3, Amélie Perrin1, Clarisse Laffon de Mazières1, Thomas Rapp4, Sophie Hermabessière1, Elodie Tournay5, Bruno Vellas1,2,3, Sandrine Andrieu1,3,5,6.
Abstract
Importance: Dementia is often underdiagnosed in nursing homes (NHs). This potentially results in inappropriate care, and high rates of emergency department (ED) transfers in particular. Objective: To assess whether systematic dementia screening of NH residents combined with multidisciplinary team meetings resulted in a lower rate of ED transfer at 12 months compared with usual care. Design, Setting, and Participants: Multicenter, cluster randomized trial with NHs as the unit of randomization. The IDEM (Impact of Systematic Tracking of Dementia Cases on the Rate of Hospitalization in Emergency Care Units) trial took place at 64 public and private NHs in France. Recruitment started on May 1, 2010, and was completed on March 31, 2012. Residents who were aged 60 years or older, had no diagnosed or documented dementia, were not bedridden, had lived in the NH for at least 1 month at inclusion, and had a life expectancy greater than 12 months were included. The residents were followed up for 18 months. The main study analyses were completed on October 14, 2016. Intervention: Two parallel groups were compared: an intervention group consisting of NHs that set up 2 multidisciplinary team meetings to identify residents with dementia and to discuss an appropriate care plan, and a control group consisting of NHs that continued their usual practice. During the inclusion period of 23 months, all residents of participating NHs who met eligibility criteria were included in the study. Main Outcomes and Measures: The primary end point (ED transfer) was analyzed at 12 months, but the residents included were followed up for 18 months.Entities:
Mesh:
Year: 2020 PMID: 32101308 PMCID: PMC7137681 DOI: 10.1001/jamanetworkopen.2020.0049
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Figure. Study Flowchart
Additional detail is shown in the eFigure in Supplement 2. ITT indicates intention-to-treat; NH, nursing home; and PP, per-protocol.
Nursing Home Characteristics
| Characteristic | Mean (SD) | ||
|---|---|---|---|
| Intervention (n = 32) | Control (n = 32) | Total (N = 64) | |
| Stratification factors at inclusion | |||
| Presence of specialized Alzheimer disease care unit, No. (%) | 13 (40.6) | 14 (43.8) | 27 (42.2) |
| Participation of nursing home investigator in REHPA geriatric network congresses, No. (%) | 29 (90.6) | 25 (78.1) | 54 (84.4) |
| GMP score | 683.4 (137.44) | 707.8 (96.33) | 695.6 (118.37) |
| Description of cluster sizes | |||
| No. of residents in the center at inclusion | 81.5 (35.17) | 99.7 (38.78) | 90.6 (37.85) |
| No. of residents included by center | 18.7 (8.71) | 25.9 (13.56) | 22.3 (11.87) |
| No. of residents included by center in intent-to-treat population | 18.4 (8.62) | 25.4 (12.99) | 21.9 (11.49) |
| No. of residents included by center in per-protocol population 1 | 18.0 (8.43) | 25.3 (12.82) | 21.6 (11.37) |
| No. of residents included by center in per-protocol population 2 | 16.0 (7.33) | 25.3 (12.82) | 21.2 (11.64) |
Abbreviations: GMP, GIR moyen pondéré (nursing home dependence score); REHPA, Recherche en Etablissement d’Hébergement pour Personnes Agées (geriatric research network in nursing homes in the Toulouse area).
Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first multidisciplinary team meeting was held for participants in the intervention group.
Included all participants in the modified intention-to-treat population who met all eligibility criteria; the first and second multidisciplinary team meetings were held for participants in the intervention group.
Participant Characteristics at Inclusion (Modified Intention-to-Treat Population)
| Characteristic | No. (%) | ||
|---|---|---|---|
| Intervention (n = 588) | Control (n = 813) | All (N = 1401) | |
| Demographic | |||
| Age, mean (SD), y | 85.0 (7.95) | 84.4 (8.19) | 84.7 (8.09) |
| Female | 422 (71.8) | 582 (71.6) | 1004 (71.7) |
| Marital status | |||
| Married | 37 (6.3) | 69 (8.6) | 106 (7.6) |
| Widowed | 371 (63.2) | 476 (59.3) | 847 (60.9) |
| Single | 133 (22.7) | 196 (24.4) | 329 (23.7) |
| Divorced | 46 (7.8) | 62 (7.7) | 108 (7.8) |
| Education | |||
| No education | 26 (4.4) | 52 (6.5) | 78 (5.6) |
| Primary school | 173 (29.5) | 225 (27.9) | 398 (28.6) |
| Primary school certificate | 208 (35.4) | 256 (31.8) | 464 (33.3) |
| Elementary school or vocational diploma | 105 (17.9) | 158 (19.6) | 263 (18.9) |
| A levels or higher diploma | 75 (12.8) | 115 (14.3) | 190 (13.6) |
| French as native language | 553 (94.0) | 757 (93.1) | 1310 (93.5) |
| Length of stay in the nursing home at inclusion, mean (SD), mo | 47.7 (68.95) | 56.5 (75.88) | 52.8 (73.18) |
| Medical history | |||
| Charlson Comorbidity Index score, mean (SD) | 2.0 (1.84) | 2.0 (1.99) | 2.0 (1.92) |
| Current smoker | 32 (5.4) | 37 (4.6) | 69 (4.9) |
| Alcohol consumption | 188 (32.0) | 227 (27.9) | 415 (29.6) |
| Vascular risk factors | 483 (82.1) | 676 (83.3) | 1159 (82.8) |
| History of psychological disorders | 326 (55.5) | 527 (64.9) | 853 (61.0) |
| History of fracture | 242 (41.2) | 366 (45.1) | 608 (43.5) |
| Progressive cognitive decline | 123 (20.9) | 167 (20.6) | 290 (20.7) |
| Mini-Mental State Examination carried out in the past 6 mo | 275 (46.9) | 474 (58.4) | 749 (53.6) |
| Mini-Mental State Examination score in the past 6 mo, mean (SD) | 22.1 (5.29) | 22.8 (5.22) | 22.5 (5.25) |
| Family history of dementia | 29 (4.9) | 28 (3.4) | 57 (4.1) |
| ≥1 Hospital admission in past 3 mo | 77 (13.1) | 95 (11.7) | 172 (12.3) |
| ≥1 Emergency department admission in past 3 mo | 48 (8.2) | 48 (5.9) | 96 (6.9) |
| Medication use at inclusion | |||
| Neuroleptics | 86 (14.6) | 143 (17.6) | 229 (16.3) |
| Benzodiazepines | 310 (52.7) | 441 (54.2) | 751 (53.6) |
| Anxiolytics | 220 (37.4) | 353 (43.4) | 573 (40.9) |
| Antidepressants | 238 (40.5) | 382 (47.0) | 620 (44.3) |
| Hypnotics | 198 (33.7) | 286 (35.2) | 484 (34.5) |
| Thymoregulators | 30 (5.1) | 62 (7.6) | 92 (6.6) |
| Psychostimulants | 238 (40.5) | 384 (47.2) | 622 (44.4) |
| Antiepileptics | 84 (14.3) | 125 (15.4) | 209 (14.9) |
| Vitamin D | 27 (4.6) | 37 (4.6) | 64 (4.6) |
| Vitamin K antagonists | 28 (4.8) | 25 (3.1) | 53 (3.8) |
| Platelet aggregation inhibitors | 214 (36.4) | 293 (36.0) | 507 (36.2) |
| Analgesics | 277 (47.1) | 369 (45.4) | 646 (46.1) |
| Proton pump inhibitors | 236 (40.1) | 332 (40.8) | 568 (40.5) |
| Nonmedicinal treatments | |||
| Physiotherapy | 245 (41.7) | 261 (32.1) | 506 (36.1) |
| Ergotherapy | 46 (7.8) | 44 (5.4) | 90 (6.4) |
| Psychomotricity | 37 (6.3) | 38 (4.7) | 75 (5.4) |
| Psychological follow-up | 146 (24.8) | 224 (27.6) | 370 (26.4) |
| Dietetic follow-up | 91 (15.5) | 112 (13.8) | 203 (14.5) |
| Speech therapy | 10 (1.7) | 5 (0.6) | 15 (1.1) |
| Other nonmedicinal treatment | 30 (5.1) | 62 (7.6) | 92 (6.6) |
First and Second MDTMs in Modified Intention-to-Treat Population, Intervention Group
| Characteristic | No./Total No. (%) (N = 588) |
|---|---|
| First MDTM | |
| Residents whose case was studied during the first MDTM | 581/588 (98.8) |
| Time spent on each case, mean (SD), min | 15.8 (7.0) |
| No. of experts participating in the first MDTM, mean (SD) | 4.2 (1.6) |
| Conclusion on dementia diagnosis | 574/581 (98.8) |
| High probability of dementia | 129/574 (22.5) |
| Absence of dementia with normal cognitive test results | 207/574 (36.1) |
| Absence of dementia with abnormal cognitive test results | 103/574 (17.9) |
| Suspicion of dementia | 107/574 (18.6) |
| Lack of data or incomplete medical file | 28/574 (4.9) |
| Symptoms present at inclusion visit | 581/581 (100) |
| Delirium syndrome | 8/581 (1.4) |
| Depressive syndrome | 243/581 (41.8) |
| Malnutrition | 141/581 (24.3) |
| High risk of fracture | 272/581 (46.8) |
| Behavioral disturbances | 153/581 (26.3) |
| Care plan proposed at the first MDTM | 580/581 (99.8) |
| Proposal for further examinations | 308/580 (53.1) |
| Laboratory tests | 207/308 (67.2) |
| Cerebral computed tomography | 101/308 (32.8) |
| Cerebral magnetic resonance imaging | 27/308 (8.8) |
| Additional psychometric evaluation | 113/308 (36.7) |
| Therapeutic proposal | 470/580 (81.0) |
| Discussion of value of specific treatment of Alzheimer disease | 64/470 (13.6) |
| Discontinuation of a psychotropic treatment | 115/470 (24.5) |
| Introduction of a psychotropic treatment | 8/470 (16.6) |
| Other changes in drug treatment | 159/470 (33.8) |
| Proposal for nondrug treatment | 271/470 (57.7) |
| Proposal of general preventive measures | 355/470 (75.5) |
| Need for immediate hospitalization | 29/580 (5.0) |
| Need for move to another nursing home | 3/580 (0.5) |
| Resident's GP informed of MDTM conclusions | 462/581 (79.5) |
| First MDTM recommendations followed by resident's GP | 273/445 (61.3) |
| Second MDTM | |
| Residents whose case was studied during the second MDTM | 401/588 (68.2) |
| Appearance of new developments since the first MDTM | 210/401 (52.4) |
| Care plan proposed at the second MDTM | 400/401 (99.8) |
| Proposal for further examinations | 105/400 (26.3) |
| New therapeutic proposal | 161/400 (40.3) |
| Discussion of the value of a specific treatment of Alzheimer disease | 23/161 (14.3) |
| Discontinuation of a psychotropic treatment | 64/161 (39.8) |
| Introduction of a psychotropic treatment | 25/161 (15.5) |
| Other drug modifications | 112/161 (69.6) |
| Specific recommendations to limit the need for emergency department | 91/400 (22.8) |
| Need for regular monitoring by the memory clinic | 21/91 (23.1) |
| Need for an outpatient specialist visit | 80/91 (87.9) |
| Need for immediate hospitalization | 6/91 (6.6) |
| Need for move to another nursing home | 2/91 (2.2) |
| Resident's GP informed of second MDTM conclusions | 351/366 (95.9) |
| Second MDTM recommendations followed by resident's GP | 235/353 (66.6) |
| First and second MDTM recommendations followed by resident's GP | 147/371 (39.6) |
Abbreviations: GP, general practitioner; MDTM, multidisciplinary team meeting.
Number of participants whose data were available.
Assessment of Intervention Effect on Primary and Secondary End Points in Modified Intention-to-Treat Population, Per-protocol Population 1, and Per-protocol Population 2
| End Point | No./Total No. (%) | Ratio (95% CI) | ||
|---|---|---|---|---|
| Intervention | Control | |||
| Modified intention-to-treat population, No. (n = 1401) | 588 | 813 | ||
| Primary end point: ED transfer during 12-mo follow-up | 95 (16.2) | 104 (12.8) | 1.32 (0.83-2.09) | .24 |
| Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI) | 20.06 (14.34-28.06) | 16.27 (11.77-22.49) | 1.23 (0.78-1.94) | .36 |
| ED transfer during 18-mo follow-up | 118 (20.1) | 145 (17.8) | 1.16 (0.71 to1.91) | .54 |
| Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI) | 18.97 (13.55-26.55) | 16.87 (12.26-23.23) | 1.12 (0.71-1.77) | .61 |
| ED transfer judged inappropriate by experts during 18-mo follow-up (n = 404) | 46/204 (22.5) | 15/200 (7.5) | 3.60 (1.90-6.84) | <.001 |
| Incidence rate of ED transfer whatever the hospital unit during 18-mo follow-up in person-years (95% CI) | 73.56 (58.95-91.79) | 74.43 (60.59-91.43) | 0.99 (0.73-1.33) | .93 |
| Subgroup analyses: ED transfer during 12-mo follow-up in the subgroups | ||||
| NHs with Alzheimer disease unit (n = 558) | 28/233 (12.0) | 52/325 (16.0) | 0.75 (0.41-1.41) | .37 |
| NHs without Alzheimer disease unit (n = 843) | 67/355 (18.9) | 52/488 (10.7) | 1.88 (1.01-3.52) | .04 |
| Public NHs (n = 781) | 59/402 (14.7) | 55/379 (14.5) | 1.00 (0.53-1.90) | .99 |
| Private NHs (n = 620) | 36/186 (19.4) | 49/434 (11.3) | 1.85 (0.97-3.55) | .06 |
| Per-protocol population 1, No. (n = 1384) | 576 | 808 | ||
| ED transfer during 12-mo follow-up | 94 (16.3) | 103 (12.7) | 1.34 (0.84-2.13) | .21 |
| Incidence rate of ED transfer during 12-mo follow-up for 100 person-years (95% CI) | 20.14 (14.38-28.22) | 16.27 (11.76-22.52) | 1.24 (0.79-1.95) | .35 |
| ED transfer during 18-mo follow-up | 116 (20.1) | 144 (17.8) | 1.17 (0.72-1.91) | .52 |
| Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI) | 19.04 (13.61-26.65) | 16.95 (12.32-23.32) | 1.12 (0.71-1.77) | .61 |
| Per-protocol population 2, No. (n = 1208) | 400 | 808 | ||
| ED transfer during 18-mo follow-up | 71 (17.8) | 144 (17.8) | 0.99 (0.57-1.73) | .97 |
| Incidence rate of ED transfer during 18-mo follow-up for 100 person-years (95% CI) | 14.29 (9.41-21.70) | 16.65 (11.84-23.41) | 0.86 (0.51-1.46) | .57 |
Abbreviations: ED, emergency department; NH, nursing home.
The intracluster correlation coefficient indicates the similarity of measurements of participants from the same cluster with those from different clusters and was estimated at 0.1129 for the primary end point.
Odds ratio for intervention vs control.
Rate ratio for intervention vs control.